PharmaCyte Biotech, Inc. (PMCB)
- Previous Close
2.1300 - Open
2.1500 - Bid 1.5400 x 200
- Ask 2.7600 x 200
- Day's Range
2.1300 - 2.2000 - 52 Week Range
1.9200 - 3.2300 - Volume
12,294 - Avg. Volume
25,561 - Market Cap (intraday)
18.597M - Beta (5Y Monthly) -0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4800 - Earnings Date Mar 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
pharmacyte.comRecent News: PMCB
Performance Overview: PMCB
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PMCB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PMCB
Valuation Measures
Market Cap
18.60M
Enterprise Value
-25.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.59
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
6.09
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-5.24%
Return on Equity (ttm)
-1.73%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.82M
Diluted EPS (ttm)
-1.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
61.21M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.93M